Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Izrael2. fázis

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

A legfontosabb adatok

Ki végzi
Sheba Medical Center
Hol
Ramat Gan (Izrael)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
33 fő, tervezett
Kezdés
2023. júl. 11.
Várható befejezés
2030. júl. 30.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
  • Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]
A regiszteradat frissítve
2025. július 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat előrehaladott glioblasztómás vagy agyi áttétet adó melanómás felnőtteket keres. Három csoport van, a betegségtől és a korábbi kezeléstől függően.

Életkor
18 éves vagy idősebb
Nem
Nők és férfiak is részt vehetnek
A betegség stádiuma
1. csoport: áttétes melanóma agyi áttétekkel, újonnan felfedezett vagy újonnan növekvő. 2. csoport: visszatért vagy növekvő glioblasztóma. 3. csoport: újonnan diagnosztizált glioblasztóma. Az 1. és 2. csoportban mérhető betegség kell.
Korábbi kezelés
1. csoport: 1 korábbi immunterápia, amely nem hatott. 2. csoport: első vonalbeli agyi sugárkezelés és fenntartó temozolomid. 3. csoport: teljes dózisú agyi sugárkezelés. Korábban nem kaphatott crizanlizumabot vagy más P-szelektin-gátlót.
Biomarker vagy leletérték
3. csoport: a daganat vizsgálata MGMT-metilálatlan típust mutat.

A részvétel fő kizáró okai

  • Az agyat és gerincvelőt körülvevő hártyákra terjedt daganat (leptomeningeális szóródás)
  • Korábbi vagy jelenlegi agyvérzés
  • Az elmúlt 2 évben autoimmun betegség, amely az immunrendszert elnyomó gyógyszert igényelt
  • Terhesség vagy szoptatás
  • Más vizsgálati gyógyszer a kezdés előtti 21 napon belül

A regiszter feltételei, szó szerint

Mind a 66 feltétel megnézéseKevesebb

Ki nem vehet részt

  • Previous life-threatening toxicity to anti-PD-1 antibody monotherapy
  • Previous exposure to Crizanlizumab or any other P-selectin inhibitor
  • Previous or current brain hemorrhage
  • The patient had, or is expected to undergo, allogeneic hematopoietic stem cell transplantation (HSCT)
  • Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study
  • Treatment with other investigational drugs within <21 days of start of day 1 of the study treatment
  • Any contraindication for treatment with nivolumab according to the product's labels; Cohort 2 (Recurrent or Progressive GB) Inclusion Criteria
  • Received first line therapy with brain irradiation and maintenance temozolamide
  • Previous life-threatening toxicity to anti-PD-1 antibody monotherapy
  • Previous exposure to Crizanlizumab or any other P-selectin inhibitor
  • Previous or current brain hemorrhage
  • Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study
  • Treatment with other investigational drugs within <21 days of start of day 1 of the study treatment
  • Any contraindication for treatment with nivolumab according to the product's labels; Cohort 3 (Newly Diagnosed Unmethylated GB) Inclusion Criteria
  • Received definitive brain irradiation
  • Patients may be treated with novo TTF (optune) per local standard
  • Previous life-threatening toxicity to anti-PD-1 antibody monotherapy
  • Previous exposure to Crizanlizumab or any other P-selectin inhibitor
  • Previous or current brain hemorrhage
  • Any other severe concurrent disease which, in the judgment of the investigator, would make the subject inappropriate for entry into this study
  • Treatment with other investigational drugs within <21 days of start of day 1 of the study treatment; Any contraindication for treatment with nivolumab according to the product's labels
  • Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 10 mg prednisone will be allowed
  • Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy
  • Measurable disease per RANO criteria on brain MRI
  • Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 20 mg prednisone will be allowed
  • Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy
  • Systemic steroid therapy for symptomatic brain disease. Note: a dose equivalent to 20 mg prednisone will be allowed
  • Auto-immune disease in the last 2 years requiring systemic immune-suppressive therapy
  • Adequate organ function defined by blood tests for blood count and chemistry
  • Adequate organ function defined by blood tests for blood count and chemistry
  • Age ≥ 18 years
  • Age ≥ 18 years
  • Have leptomeningeal spread
  • The patient had a contraindication for undergoing brain MRI
  • Pregnant or lactating
  • Estimated life expectancy at least 3 months
  • Have with recurrent or persistent GB
  • Have Eastern Cooperative Oncology Group (ECOG) performance status <2
  • Women of childbearing potential practicing an acceptable method of birth control
  • Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent
  • Have leptomeningeal spread
  • The patient had, or is expected to undergo, allogeneic HSCT
  • The patient had a contraindication for undergoing brain MRI
  • Pregnant or lactating
  • Estimated life expectancy at least 3 months
  • Histologically confirmed newly diagnosed GB
  • Tumor test result shows MGMT unmethylated type
  • Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Women of childbearing potential practicing an acceptable method of birth control
  • Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent
  • Have leptomeningeal spread
  • The patient had, or is expected to undergo, allogeneic HSCT
  • The patient had a contraindication for undergoing brain MRI
  • Be pregnant or lactating

Egyéb feltételek

  • Cohort 1 (MBM) Inclusion Criteria
  • Age ≥ 18 years
  • Estimated life expectancy at least 3 months
  • Have metastatic melanoma with primarily diagnosed or newly progressing brain metastases
  • Was treated with 1 prior systemic line of immunotherapy - either PD-1 inhibitor monotherapy or combined CTLA4 and PD-1 antibodies or another investigational combination of immunotherapy. Patients with BRAF-mutant melanoma who have also received BRAF mutation targeted therapy are also eligible
  • Have failed prior immunotherapy line, either due to primary resistance or acquired resistance
  • Have measurable disease defined by RECIST criteria and have at least one, non-previously irradiated brain metastasis of at least 1-cm short diameter. Otherwise, previously irradiated lesions should present with enlargement following radiation therapy
  • Is clinically stable with no neurological deficits. Patients may receive steroid supportive therapy up to 10 mg of prednisone or the equivalent
  • Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate organ function defined by blood tests for blood count and chemistry
  • Women of childbearing potential practicing an acceptable method of birth control
  • Understand study procedures and willingness to comply for the entire duration of the study and to give written informed consent

Helyszínek itt: Izrael

  • Sheba medical centerRamat Gan, IzraelContact: Ronnie Shapira, MDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

A single-center, open-label, non-randomized phase I/II study to evaluate the efficacy, safety and tolerance of crizanlizumab monotherapy and in combination with nivolumab in patients with advanced glioblastoma (GB) who exhausted standard of care (SOC) therapy, patients with metastatic brain melanoma (MBM) and patients with newly diagnosed unmethylated GB.

A teljes eredeti leírásKevesebb

Subjects will be screened for up to 28 days prior to treatment initiation. Eligible subjects will be allocated to one of 3 cohorts:

Cohort 1: Patients with metastatic melanoma with primarily diagnosed or newly progressing brain metastases who failed immunotherapy.

Cohort 2: Patients with recurrent or progressing GB following primary radiation therapy and temozolomide. Patients may have failed up to 2 prior systemic treatment lines (including temozolomide as adjuvant therapy) and are candidates for further treatment.

Cohort 3: Patients with newly diagnosed GB who were evaluated for methylguanine-DNA methyltransferase(MGMT) methylation status and have un-methylated MGMT promotor-therefore, they are not candidates for maintenance temozolomide therapy.

A vizsgálat 3 csoportja

  • Cohort 1 metastatic melanoma with brain metastases who failed immunotherapyA vizsgált kezelés

    The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression

  • Cohort 2 - Patients with recurrent or progressing GB following radiation and temozolamide.A vizsgált kezelés

    The first 3 subjects enrolled to Cohort 1 and Cohort 2 will receive crizanlizumab 5 mg/kg at Cycle 1 Day 1 (C1D1) and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks until disease progression The subsequent 8 patients will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by 5 mg/kg every 4 weeks plus nivolumab 3mg/kg every 2 weeks until disease progression

    Kezelés: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO] és Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]

  • Cohort 3: Patients with newly diagnosed GBA vizsgált kezelés

    crizanlizumab starting from 4 weeks after completing radiation therapy. The first 2 subjects will receive crizanlizumab 2.5 mg/kg at C1D1 and C1D15 followed by crizanlizumab 5 mg/kg every 4 weeks. The subsequent 6 subjects will receive crizanlizumab 5 mg/kg at C1D1 and C1D15 followed by crizanlizumab every 4 weeks. Treatment will continue for up to 12 months or until disease progression or unacceptable toxicity.

    Kezelés: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open Label Phase 2 Study of Intravenously Administered Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2025. július 22.